Erica Daina

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3554009/publications.pdf

Version: 2024-02-01

37 papers	4,122 citations	331670 21 h-index	377865 34 g-index
37 all docs	37 docs citations	37 times ranked	4264 citing authors

#	Article	IF	Citations
1	Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatment. Nephrology Dialysis Transplantation, 2023, 38, 283-290.	0.7	12
2	Morphofunctional Effects of C5 Convertase Blockade in Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Report of Two Cases with Evidence of Terminal Complement Activation. Nephron, 2020, 144, 195-203.	1.8	4
3	C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial. American Journal of Kidney Diseases, 2019, 74, 224-238.	1.9	45
4	Urinary proteome signature of Renal Cysts and Diabetes syndrome in children. Scientific Reports, 2019, 9, 2225.	3.3	15
5	Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complexâ€“Mediated Membranoproliferative GN. Journal of the American Society of Nephrology: JASN, 2018, 29, 283-294.	6.1	89
6	Outrageous prices of orphan drugs: a call for collaboration. Lancet, The, 2018, 392, 791-794.	13.7	132
7	Biallelic variants in the ciliary gene TMEM67 cause RHYNS syndrome. European Journal of Human Genetics, 2018, 26, 1266-1271.	2.8	12
8	Unravelling the pathophysiology of C3G/IC-MPGN and how to predict disease progression and orient therapies. Molecular Immunology, 2017, 89, 178.	2.2	0
9	Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. Molecular Immunology, 2016, 71, 131-142.	2.2	126
10	Liver transplantation for aHUS: still needed in the eculizumab era?. Pediatric Nephrology, 2016, 31, 759-768.	1.7	22
11	Rare Diseases in Europe: from a Wide to a Local Perspective. Israel Medical Association Journal, 2016, 18, 359-63.	0.1	45
12	A Multidrug, Antiproteinuric Approach to Alport Syndrome: A Ten-Year Cohort Study. Nephron, 2015, 130, 13-20.	1.8	9
13	The Italian National Rare Diseases Registry. Blood Transfusion, 2014, 12 Suppl 3, s606-13.	0.4	18
14	Monogenic diseases that can be cured by liver transplantation. Journal of Hepatology, 2013, 59, 595-612.	3.7	111
15	Eculizumab in a Patient with Dense-Deposit Disease. New England Journal of Medicine, 2012, 366, 1161-1163.	27.0	140
16	Discordant phenotype in monozygotic twins with renal coloboma syndrome and a PAX2 mutation. Pediatric Nephrology, 2012, 27, 1989-1993.	1.7	19
17	Natural History and Outcome of Hepatic Vascular Malformations in a Large Cohort of Patients with Hereditary Hemorrhagic Teleangiectasia. Digestive Diseases and Sciences, 2011, 56, 2166-2178.	2.3	106
18	Relative Role of Genetic Complement Abnormalities in Sporadic and Familial aHUS and Their Impact on Clinical Phenotype. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1844-1859.	4.5	818

#	Article	IF	Citations
19	Enzyme Replacement Therapy and Fabry Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 371-378.	4.5	21
20	Rare Autoimmune Diseases. Advances in Experimental Medicine and Biology, 2010, 686, 365-374.	1.6	0
21	Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. Thrombosis and Haemostasis, 2009, 101, 233-238.	3.4	85
22	Liver-Kidney Transplantation to Cure Atypical Hemolytic Uremic Syndrome. Journal of the American Society of Nephrology: JASN, 2009, 20, 940-949.	6.1	154
23	Why rare diseases are an important medical and social issue. Lancet, The, 2008, 371, 2039-2041.	13.7	457
24	Introduction: Hereditary Hemorrhagic Telangiectasia as a Rare Disease. Current Pharmaceutical Design, 2006, 12, 1171-1172.	1.9	7
25	Outcome of Renal Transplantation in Patients with Nonâ€“Shiga Toxinâ€“Associated Hemolytic Uremic Syndrome: Prognostic Significance of Genetic Background. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 88-99.	4.5	201
26	Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report. Blood, 2005, 106, 925-928.	1.4	57
27	Takayasu's arteritis: A study of 104 Italian patients. Arthritis and Rheumatism, 2005, 53, 100-107.	6.7	273
28	Left main stem patch plasty and aortic root homograft in Takayasu's disease. Annals of Thoracic Surgery, 2004, 77, 314-317.	1.3	9
29	Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Human Molecular Genetics, 2003, 12, 3385-3395.	2.9	291
30	Tackling the Problem of Rare Diseases in Public Health: The Italian Approach. Public Health Genomics, 2003, 6, 123-124.	1.0	8
31	von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood, 2002, 100, 778-785.	1.4	200
32	The Molecular Basis of Familial Hemolytic Uremic Syndrome. Journal of the American Society of Nephrology: JASN, 2001, 12, 297-307.	6.1	263
33	Interleukin-6 and RANTES in Takayasu Arteritis. Circulation, 1999, 100, 55-60.	1.6	216
34	Mycophenolate Mofetil for the Treatment of Takayasu Arteritis: Report of Three Cases. Annals of Internal Medicine, 1999, 130, 422.	3.9	129
35	CONFERENCE. Lancet, The, 1994, 343, 1560-1561.	13.7	7
36	Methylprednisolone dosage effects on peripheral lymphocyte subpopulations and eicosanoid synthesis. Kidney International, 1992, 42, 981-990.	5.2	21

#	Article	IF	Citations
37	Lupus Nephritis. , 0, , 244-252.		0